Search

Recursion Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

3.63 5.83

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.61

Максимум

3.66

Ключови измерители

By Trading Economics

Приходи

-14M

-131M

Продажби

1.2M

7.7M

EPS

-0.25

Марж на печалбата

-1,708.018

Служители

600

EBITDA

-10M

-113M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+77.13% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

135M

1.8B

Предишно отваряне

-2.2

Предишно затваряне

3.63

Настроения в новините

By Acuity

34%

66%

71 / 339 Класиране в Healthcare

Recursion Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.09.2026 г., 20:08 ч. UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3.09.2026 г., 23:21 ч. UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2.09.2026 г., 23:06 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

1.09.2026 г., 20:09 ч. UTC

Recursion Pharmaceuticals Inc. shares are lower, following broader market declines amid rising oil prices and increasing U.S. Treasury yields. No specific company news was identified.

31.08.2026 г., 23:06 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment reflects recent comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

28.08.2026 г., 23:51 ч. UTC

Recursion Pharmaceuticals Inc shares are higher in after-market hours, following three consecutive lower finishes. No specific news was identified to explain the movement.

27.08.2026 г., 23:02 ч. UTC

Recursion Pharmaceuticals Inc shares are trading higher in after-market hours. No specific news was identified to explain the price movement.

26.08.2026 г., 20:08 ч. UTC

Correlated Moves

Recursion Pharmaceuticals is declining amid a broader downturn in the Biotechnology sub-sector, with the ARK Genomic Revolution ETF also experiencing losses.

25.08.2026 г., 23:01 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

24.08.2026 г., 20:02 ч. UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21.08.2026 г., 20:06 ч. UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20.08.2026 г., 20:06 ч. UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19.08.2026 г., 23:01 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18.08.2026 г., 20:04 ч. UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17.08.2026 г., 19:36 ч. UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12.08.2026 г., 19:56 ч. UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11.08.2026 г., 19:36 ч. UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10.08.2026 г., 20:06 ч. UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7.08.2026 г., 23:26 ч. UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6.08.2026 г., 23:26 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5.08.2026 г., 23:41 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4.08.2026 г., 23:31 ч. UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3.08.2026 г., 20:03 ч. UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31.07.2026 г., 23:32 ч. UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30.07.2026 г., 23:26 ч. UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29.07.2026 г., 22:51 ч. UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28.07.2026 г., 23:11 ч. UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27.07.2026 г., 23:46 ч. UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24.07.2026 г., 23:11 ч. UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23.07.2026 г., 19:16 ч. UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

Сравнение с други в отрасъла

Ценова промяна

Recursion Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

77.13% нагоре

12-месечна прогноза

Среден 6.43 USD  77.13%

Висок 8 USD

Нисък 5.3 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Recursion Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

1

Купи

3

Задържане

0

Продай

Настроение

By Acuity

71 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat